Literature DB >> 34202364

Cystic Fibrosis Human Organs-on-a-Chip.

Herbert Luke Ogden1, Hoyeol Kim2, Kathryn A Wikenheiser-Brokamp3,4,5, Anjaparavanda P Naren1,2, Kyu Shik Mun2,6.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene: the gene product responsible for transporting chloride and bicarbonate ions through the apical membrane of most epithelial cells. Major clinical features of CF include respiratory failure, pancreatic exocrine insufficiency, and intestinal disease. Many CF animal models have been generated, but some models fail to fully capture the phenotypic manifestations of human CF disease. Other models that better capture the key characteristics of the human CF phenotype are cost prohibitive or require special care to maintain. Important differences have been reported between the pathophysiology seen in human CF patients and in animal models. These limitations present significant limitations to translational research. This review outlines the study of CF using patient-derived organs-on-a-chip to overcome some of these limitations. Recently developed microfluidic-based organs-on-a-chip provide a human experimental model that allows researchers to manipulate environmental factors and mimic in vivo conditions. These chips may be scaled to support pharmaceutical studies and may also be used to study organ systems and human disease. The use of these chips in CF discovery science enables researchers to avoid the barriers inherent in animal models and promote the advancement of personalized medicine.

Entities:  

Keywords:  CFTR; cystic fibrosis; organ-on-a-chip; personalized medicine

Year:  2021        PMID: 34202364     DOI: 10.3390/mi12070747

Source DB:  PubMed          Journal:  Micromachines (Basel)        ISSN: 2072-666X            Impact factor:   2.891


  100 in total

Review 1.  Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.

Authors:  Pascale Fanen; Adeline Wohlhuter-Haddad; Alexandre Hinzpeter
Journal:  Int J Biochem Cell Biol       Date:  2014-03-12       Impact factor: 5.085

2.  Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility.

Authors:  Daniel P Cook; Michael V Rector; Drake C Bouzek; Andrew S Michalski; Nicholas D Gansemer; Leah R Reznikov; Xiaopeng Li; Mallory R Stroik; Lynda S Ostedgaard; Mahmoud H Abou Alaiwa; Michael A Thompson; Y S Prakash; Ramaswamy Krishnan; David K Meyerholz; Chun Y Seow; David A Stoltz
Journal:  Am J Respir Crit Care Med       Date:  2016-02-15       Impact factor: 21.405

3.  Engineering human islet organoids from iPSCs using an organ-on-chip platform.

Authors:  Tingting Tao; Yaqing Wang; Wenwen Chen; Zhongyu Li; Wentao Su; Yaqiong Guo; Pengwei Deng; Jianhua Qin
Journal:  Lab Chip       Date:  2019-03-13       Impact factor: 6.799

4.  Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis.

Authors:  Xingshen Sun; Hongshu Sui; John T Fisher; Ziying Yan; Xiaoming Liu; Hyung-Ju Cho; Nam Soo Joo; Yulong Zhang; Weihong Zhou; Yaling Yi; Joann M Kinyon; Diana C Lei-Butters; Michelle A Griffin; Paul Naumann; Meihui Luo; Jill Ascher; Kai Wang; Timothy Frana; Jeffrey J Wine; David K Meyerholz; John F Engelhardt
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

5.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

6.  Cultures of human tracheal gland cells of mucous or serous phenotype.

Authors:  Walter E Finkbeiner; Lorna T Zlock; Irum Mehdi; Jonathan H Widdicombe
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-12-09       Impact factor: 2.416

7.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Authors:  Jane C Davies; Claire E Wainwright; Gerard J Canny; Mark A Chilvers; Michelle S Howenstine; Anne Munck; Jochen G Mainz; Sally Rodriguez; Haihong Li; Karl Yen; Claudia L Ordoñez; Richard Ahrens
Journal:  Am J Respir Crit Care Med       Date:  2013-06-01       Impact factor: 21.405

Review 8.  The cystic fibrosis of exocrine pancreas.

Authors:  Michael Wilschanski; Ivana Novak
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 9.  The Cells of the Islets of Langerhans.

Authors:  Gabriela Da Silva Xavier
Journal:  J Clin Med       Date:  2018-03-12       Impact factor: 4.241

10.  Fixing cystic fibrosis by correcting CFTR domain assembly.

Authors:  Tsukasa Okiyoneda; Gergely L Lukacs
Journal:  J Cell Biol       Date:  2012-10-15       Impact factor: 10.539

View more
  3 in total

Review 1.  Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics.

Authors:  Deborah M Cholon; Martina Gentzsch
Journal:  Curr Opin Pharmacol       Date:  2022-04-21       Impact factor: 4.768

2.  Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.

Authors:  Sergey K Zyryanov; Elena A Ushkalova; Elena I Kondratyeva; Olga I Butranova; Yulia A Kondakova
Journal:  Biomedicines       Date:  2022-05-02

Review 3.  Organ-On-A-Chip: A Survey of Technical Results and Problems.

Authors:  Alex Ede Danku; Eva-H Dulf; Cornelia Braicu; Ancuta Jurj; Ioana Berindan-Neagoe
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.